Our top pick for
NantHealth Inc is a health information services business based in the US. NantHealth shares (NH) are listed on the NASDAQ and all prices are listed in US Dollars. NantHealth employs 352 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.80|
|52-week range||$1.56 - $5.29|
|50-day moving average||$1.84|
|200-day moving average||$2.29|
|Wall St. target price||$3.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||4.65%|
|1 month (2021-09-22)||5.26%|
|3 months (2021-07-22)||-12.62%|
|6 months (2021-04-22)||-32.33%|
|1 year (2020-10-22)||-25.93%|
|2 years (2019-10-22)||153.45%|
|3 years (2018-10-22)||25.87%|
|5 years (2016-10-21)||13.45|
|Revenue TTM||$69.7 million|
|Gross profit TTM||$48.7 million|
|Return on assets TTM||-8.76%|
|Return on equity TTM||0%|
|Market capitalisation||$198.2 million|
TTM: trailing 12 months
There are currently 1.1 million NantHealth shares held short by investors – that's known as NantHealth's "short interest". This figure is 6.4% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting NantHealth shares can be evaluated.
NantHealth's "short interest ratio" (SIR) is the quantity of NantHealth shares currently shorted divided by the average quantity of NantHealth shares traded daily (recently around 152431.52777778). NantHealth's SIR currently stands at 7.2. In other words for every 100,000 NantHealth shares traded daily on the market, roughly 7200 shares are currently held short.
However NantHealth's short interest can also be evaluated against the total number of NantHealth shares, or, against the total number of tradable NantHealth shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NantHealth's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 NantHealth shares in existence, roughly 10 shares are currently held short) or 0.0368% of the tradable shares (for every 100,000 tradable NantHealth shares, roughly 37 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NantHealth.
Find out more about how you can short NantHealth stock.
We're not expecting NantHealth to pay a dividend over the next 12 months.
Over the last 12 months, NantHealth's shares have ranged in value from as little as $1.56 up to $5.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NantHealth's is 1.7503. This would suggest that NantHealth's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
NantHealth, Inc. , together with its subsidiaries, operates as a healthcare IT company in the United States and internationally. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers GPS Cancer, a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing; Omics Core, an in-vitro diagnostic built on a custom-targeted whole exome sequencing platform; and Quadris, a data solution that includes multi-data analysis, reporting, and professional service. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.